Argenx SE
Belgian-Dutch biopharmaceutical company specialising in immunology
ARGX Euronext Brussels · home listing
ARGX Nasdaq
ISIN NL0010832176 SEC CIK 1697862 LEI 7245009C5FZE6G9ODQ71
Follow Argenx
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $4.2B | $1.3B |
| FY24 | $2.2B | $833M |
| FY23 | $1.2B | −$295.1M |
| FY22 | $400.7M | −$709.6M |
| FY21 | $497.3M | −$408.3M |
| FY20 | $41.2M | −$608.5M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 89.1% | 25.4% | 31.1% |
| FY24 | 89.6% | −1% | 38.1% |
| FY23 | 90.1% | −35.7% | −24.8% |
| FY22 | 92.7% | −179.8% | −177.1% |
| FY21 | - | −70.1% | −82.1% |
| FY20 | - | −1158.1% | −1475.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $679M |
| FY24 | −$84.5M |
| FY23 | −$421.1M |
| FY22 | −$863.6M |
| FY21 | −$610.4M |
| FY20 | −$399.5M |
- Argenx
- Healthcare median
Show the numbers
| Year | Argenx | Healthcare median |
|---|---|---|
| FY25 | 31.1% | −30.6% |
| FY24 | 38.1% | −47% |
| FY23 | −24.8% | −58% |
| FY22 | −177.1% | −80.4% |
| FY21 | −82.1% | −71.9% |
| FY20 | −1475.3% | −62.2% |